{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24"],"submitter":["van Hemert ND"],"pubmed_abstract":["<h4>Objectives</h4>In an all-comers cohort undergoing percutaneous coronary intervention (PCI), we aimed to assess prevalence of high bleeding risk (HBR) patients and impact of HBR and dual antiplatelet therapy (DAPT) on clinical events.<h4>Background</h4>HBR represents a complex subgroup of patients undergoing PCI.<h4>Methods</h4>In the ReCre8 trial, patients undergoing PCI were stratified for troponin status and diabetes and randomized to a permanent polymer zotarolimus-eluting- or polymer-free amphilimus-eluting stent. Patients were treated with 12 months (troponin-positive) or one month (troponin-negative) of DAPT. We evaluated clinical outcomes in patients with and without HBR according to the Academic Research Consortium for High Bleeding Risk criteria.<h4>Results</h4>From a total of 1488 patients included in this subanalysis, 406 patients (27.3 %) were identified as being at HBR. Among HBR patients, target-lesion failure (TLF) was similar after one year yet was higher after three years (13.3 % vs. 9.1 %; p = 0.013), compared to non-HBR patients. There was no difference in Bleeding Academic Research Consortium (BARC) 3 to 5 bleeding, however BARC 2 to 5 bleeding was higher after three years with 4.9 % vs. 3.0 % (p = 0.037). There were no differences between troponin-positive (12-months DAPT) and -negative (1-month DAPT) HBR patients with respect to ischemic and bleeding outcomes.<h4>Conclusions</h4>In this all-comers population of PCI patients, a higher TLF rate among HBR patients at long-term follow-up was found, underlining the complexities involving treatment of HBR patients. We did not observe statistically significant differences in BARC 3 to 5 bleeding between HBR and non-HBR patients regardless of DAPT duration.<h4>Clinical trial registration</h4>URL: http://www.clinicaltrials.gov, unique identifier: NCT02328898."],"journal":["American heart journal plus : cardiology research and practice"],"pagination":["100227"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10978429"],"repository":["biostudies-literature"],"pubmed_title":["High bleeding risk in patients undergoing percutaneous coronary intervention with drug-eluting stent implantation: ReCre8 subanalysis."],"pmcid":["PMC10978429"],"pubmed_authors":["Rittersma SZ","van der Harst P","Kraaijeveld AO","Frambach P","Stein M","Agostoni P","Voskuil M","Stella PR","ReCre8 Study Investigators","Meijs TA","Rozemeijer R","van Hemert ND","Leenders GEH"],"additional_accession":[]},"is_claimable":false,"name":"High bleeding risk in patients undergoing percutaneous coronary intervention with drug-eluting stent implantation: ReCre8 subanalysis.","description":"<h4>Objectives</h4>In an all-comers cohort undergoing percutaneous coronary intervention (PCI), we aimed to assess prevalence of high bleeding risk (HBR) patients and impact of HBR and dual antiplatelet therapy (DAPT) on clinical events.<h4>Background</h4>HBR represents a complex subgroup of patients undergoing PCI.<h4>Methods</h4>In the ReCre8 trial, patients undergoing PCI were stratified for troponin status and diabetes and randomized to a permanent polymer zotarolimus-eluting- or polymer-free amphilimus-eluting stent. Patients were treated with 12 months (troponin-positive) or one month (troponin-negative) of DAPT. We evaluated clinical outcomes in patients with and without HBR according to the Academic Research Consortium for High Bleeding Risk criteria.<h4>Results</h4>From a total of 1488 patients included in this subanalysis, 406 patients (27.3 %) were identified as being at HBR. Among HBR patients, target-lesion failure (TLF) was similar after one year yet was higher after three years (13.3 % vs. 9.1 %; p = 0.013), compared to non-HBR patients. There was no difference in Bleeding Academic Research Consortium (BARC) 3 to 5 bleeding, however BARC 2 to 5 bleeding was higher after three years with 4.9 % vs. 3.0 % (p = 0.037). There were no differences between troponin-positive (12-months DAPT) and -negative (1-month DAPT) HBR patients with respect to ischemic and bleeding outcomes.<h4>Conclusions</h4>In this all-comers population of PCI patients, a higher TLF rate among HBR patients at long-term follow-up was found, underlining the complexities involving treatment of HBR patients. We did not observe statistically significant differences in BARC 3 to 5 bleeding between HBR and non-HBR patients regardless of DAPT duration.<h4>Clinical trial registration</h4>URL: http://www.clinicaltrials.gov, unique identifier: NCT02328898.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-06-01T09:52:15.736Z","creation":"2025-04-06T07:46:44.307Z"},"accession":"S-EPMC10978429","cross_references":{"pubmed":["38560639"],"doi":["10.1016/j.ahjo.2022.100227"]}}